Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Minority Interest (2024 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Minority Interest for 2 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Minority Interest changed 0.0% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, changed 0.0% year-over-year, with the annual reading at $7.0 million for FY2025, 0.0% changed from the prior year.
  • Minority Interest for Q4 2025 was $7.0 million at Ultragenyx Pharmaceutical, roughly flat from $7.0 million in the prior quarter.
  • The five-year high for Minority Interest was $7.0 million in Q3 2024, with the low at $7.0 million in Q3 2024.